🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Adjuvant chemotherapy compared to observation in resected biliary tract cancers: Survival meta-analysis of phase-III controlled trials European J Cancer doi.org/10.1016/j.ejca… 👉4 trials: BILCAP, ASCOT, BCAT, PRODIGE-12 👉only ASCOT met 1° EP 🧐Not convincing, we need to do

Tumor-Infiltrating Clonal Hematopoiesis NEJM doi.org/10.1056/NEJMoa… 👉CHIP-derived immune cells remodel tumor immune microenvironment 👉26% of pts with CHIP had TI-CH 👉TET2 mut strongest genetic predictor of TI-CH 👉TI-CH increased risk of recurrence or death ESMO - Eur. Oncology

The impact of neoadjuvant therapy in left-sided resectable pancreatic cancer doi.org/10.1016/j.anno… Annals of Oncology 🔎multicenter study 👉Left-sided PDAC associated with worse OS 👉Neoadj. Tx in left-sided RPC associated with improved OS vs upfront surgery 🧐Side matters in GI

Neo-adjuvant FOLFOX +/- panitumumab for KRAS-wt locallyCRC 🔎 biomarker analysis of FOxTROT doi.org/10.1016/j.anno… Annals of Oncology 👉non-sign. improvement in TTR w/ panitumumab + FOLFOX in RAS/BRAF-WT, EREG/AREG high pts 🧐we need trial in biomarker-defined population ESMO - Eur. Oncology

Advances and challenges in targeted therapies for HER2-amplified CRC European J Cancer doi.org/10.1016/j.ejca… 👏Excellent review 👉HER2 overexpressed in ~6% of RAS WT 👉Trastuzumab/Tucatinib & T-Deruxtecan FDA approved ❓but still many open questions ESMO - Eur. Oncology

Cardiological adverse events in HCC receiving immunotherapy: Influence of comorbidities and clinical outcomes European J Cancer doi.org/10.1016/j.ejca… 👉MACE in 7.3 % of patients, associated with worse outcome 🧐CARDIOSOR scale valuable tool for risk assessment ESMO - Eur. Oncology EASL Education

🔥CHMP recommended a conditional marketing authorisation for zanidatamab for the treatment of HER2-positive biliary tract cancer🔥 👉based on HERIZON-BTC: ORR 41% 👉Phs-III in 1st line ongoing ESMO - Eur. Oncology EASL Education ILCA Cholangiocarcinoma Foundation @livertwitter

Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for HCC The Lancet doi.org/10.1016/S0140-… 🔎CheckMate 9DW 👉mOS 23·7 vs 20·6 mo 👉ORR 36 vs 13% 👉Consistent efficacy in ALBI 1 and 2 🧐Great new option for 1st line HCC ESMO - Eur. Oncology EASL Education ILCA

🔥EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma🔥 Journal of Hepatology doi.org/10.1016/j.jhep… 👉get the lastest update on the diagnosis and management of eCCA ESMO - Eur. Oncology EASL Education ILCA #livertwitter

Outcomes by liver function in HCC treated with nivo plus ipi vs lenva or sora 🔎 CheckMate 9DW phs-III 👉ALBI 1: mOS 35.4 mo, ORR 37% 👉ALBI 2: mOS 16.9 mo, ORR 35% 🧐Effective independent of liver function 🧐No new safety concerns in ALBI 2 ESMO - Eur. Oncology EASL Education ILCA

🆕ESMO guideline podcast🎧: Annals of Oncology Editor-in-Chief Tom Powles discusses the ESMO ESMO Clinical Practice Guideline for hepatocellular carcinoma with Arndt Vogel tinyurl.com/msfbh7fe For the full Clinical Practice Guideline see doi.org/10.1016/j.anno…

🔥hot off the press🔥 Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study Journal of Hepatology doi.org/10.1016/j.jhep… 👉36-month OS 17.0% versus 7.6% 👉no new safety signals 🧐Confirmative! ESMO - Eur. Oncology EASL Education

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC JHEP Reports doi.org/10.1016/j.jhep… 👉FGF21 is central metabolic regulator 👉FGF21 negative prognostic marker 🧐We need biomarker to guide treatment in HCC ESMO - Eur. Oncology EASL Education ILCA

Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors Nature Communications doi.org/10.1038/s41467… 👉undetectable ctDNA after pembrolizumab were more likely to have pCR and higher 2-year EFS rate 🧐ctDNA helpful for decision

🔥hot off the press: Redefining cancer care: the case for an onco-gastroenterology subspecialty Nature Reviews Gastroenterology & Hepatology bit.ly/3FnDxdV 👉Multidisciplinary team work is key 👉Onco-gastroenterology as a distinct subspecialty ESMO - Eur. Oncology EASL Education ILCA